how to keep losing weight after semaglutide Woman shares journey of loss and gain using Patients regain weight rapidly after

Dietary Guidelines for Americans 2025-2030

2019;68(Supplement 1):54OR

A Review of Practical Issues on the Use of Glucagon-Like Peptide-1 Receptor Agonists for the Management of Type 2 Diabete

Manoharan is with Huntsville Hospital/University of Alabama at Birmingham Huntsville Campus in Huntsville, Alabama

Semaglutide is a GLP-1 receptor agonist licensed for type 2 diabetes and weight management in the UK No direct mechanism exists linking semaglutide to reduced oestrogen production at the ovarian level Weight loss decreases adipose tissue containing aromatase enzyme, potentially reducing peripheral oestrogen conversion, particularly in postmenopausal women Semaglutide does not affect oral contraceptive efficacy and should be discontinued at least two months before planned pregnancy Women experiencing menstrual irregularities or severe menopausal symptoms during treatment should seek medical advice for appropriate investigation Table of Contents Understanding Ozempic and Hormonal Effects Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist licensed in the UK for the treatment of type 2 diabetes mellitus and, at higher doses under the brand name Wegovy, for weight management in adults with obesity or overweight with weight-related comorbidities

These complications are extensive and diverse, encompassing metabolic disorders such as type 2 diabetes 2 , dyslipidemia 3 , cardiovascular diseases 4 and an increased overall mortality risk 5